Oracle (Redwood Shores, CA) announced the release of Oracle Argus Safety Suite 5.1, its integrated pharmacovigilance suite that helps users meet regulatory compliance by supporting drug safety processes across the R&D spectrum, from clinical development through post-marketing.
The new release includes enhancements to Oracle Argus Safety (advanced reporting features, including dashboards and metrics, and new automation functionality for case processing), Oracle Argus Insight, and Oracle Argus Perceptive.
“Health sciences organizations recognize that they can significantly reduce the costs and risks associated with bringing drugs and devices to market by identifying and effectively managing safety issues early,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “The Oracle Argus Safety Suite has proven effective in helping organizations of all sizes ensure regulatory compliance and improve the overall safety of therapies.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.